Evommune Inc. (NYSE: EVMN) shares surged approximately 27% in intraday trading today, rebounding sharply from Tuesday’s closing price of $5.16. The rally follows a steep…
October 26, 2026
Nuvectis Reports 40% Response Rate for NXP200 in High-Grade Glioma, Including Three Complete Responses
Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical-stage company developing therapies for complement-related conditions and cancer, announced on October 26, 2026 expanded Phase 1b data for…
Safe Harbor Financial Holdings (NASDAQ: SHFS) rose 44% midday to about $0.13, up from Tuesday’s $0.0899 close. The gain followed Nasdaq’s approval of an additional…
Key Points Myriad Genetics agreed to sell its Prenatal Health testing business to Labcorp for $210 million in cash, plus the value of inventory at…
Key Points Daré Bioscience is the premier sponsor of a clinician education program focused on managing menopause after breast cancer. The October 20 event in…
Key Points Hims & Hers has launched Hers in Australia, expanding its women’s health services across hair regrowth, menopause, perimenopause and weight management. The launch…
FiscalNote Holdings Inc. (OTC: NOTE) shares climbed 20.42% today by mid-day. Trading volume reached 403,952 shares, approaching its average daily volume of approximately 509,067 shares…
October 13 is Metastatic Breast Cancer Awareness Day, which spotlights the stage of breast cancer that still has no cure and the emerging companies working…
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company developing oral therapeutics, announced on October 7, 2026 that Health Canada has approved TLANDO (testosterone undecanoate) capsules…
PDS Biotechnology Corporation (NASDAQ: PDSB) shares surged 43.62% to $1.07 as of 12:05 p.m. ET Monday, gaining $0.33 from Friday’s $0.75 close. The stock traded…
September 24, 2026
Nuvectis’ NXP200 Receives China Breakthrough Therapy Designation for BRAF V600-Mutant High-Grade Glioma
Key Points Nuvectis Pharma said China’s Center for Drug Evaluation granted Breakthrough Therapy Designation to NXP200 for recurrent or progressive BRAF V600-mutant high-grade glioma. NXP200,…
PDS Biotechnology Corporation (NASDAQ: PDSB) is up 46.65% at $0.5853 in the latest regular session, after trading between $0.41 and $0.76. The sharp advance followed…